Cargando…

Gefitinib (‘Iressa’, ZD1839) and new epidermal growth factor receptor inhibitors

The epidermal growth factor receptor (EGFR) is a promising target for cancer therapy and a number of EGFR-targeted agents have been developed. Those most advanced in development are the EGFR tyrosine kinase inhibitors gefitinib (‘Iressa’, ZD1839) and erlotinib (‘Tarceva’, OSI-774), and the monoclona...

Descripción completa

Detalles Bibliográficos
Autores principales:	Blackledge, G, Averbuch, S
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2004
Materias:	Minireview
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409596/ https://www.ncbi.nlm.nih.gov/pubmed/14760365 http://dx.doi.org/10.1038/sj.bjc.6601550

Ejemplares similares

Gefitinib (ZD1839, Iressa™) as palliative treatment in recurrent or metastatic head and neck cancer
por: Kirby, A M, et al.
Publicado: (2006)

Gefitinib (‘Iressa’, ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2
por: Nutt, J E, et al.
Publicado: (2004)

Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer
por: Parra, H S, et al.
Publicado: (2004)

Additive interaction of gefitinib (‘Iressa’, ZD1839) and ionising radiation in human tumour cells in vitro
por: Giocanti, N, et al.
Publicado: (2004)

Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 (‘Iressa’)
por: Sewell, J M, et al.
Publicado: (2002)

Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells
por: Okubo, S, et al.
Publicado: (2004)

Molecular mechanisms underlying the interaction between ZD1839 (‘Iressa’) and cisplatin/5-fluorouracil
por: Magné, N, et al.
Publicado: (2003)

Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines
por: Maddineni, S B, et al.
Publicado: (2005)

ZD1839 (‘Iressa’), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model
por: Williams, K J, et al.
Publicado: (2002)

Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 (‘Iressa’)
por: Magné, N, et al.
Publicado: (2002)

A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839)
por: Höpfner, M, et al.
Publicado: (2003)

Sequence-dependent effects of ZD1839 (‘Iressa’) in combination with cytotoxic treatment in human head and neck cancer
por: Magné, N, et al.
Publicado: (2002)

Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme
por: Mu, Xin-Lin, et al.
Publicado: (2004)

Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA)
por: Kimura, H, et al.
Publicado: (2007)

Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA)
por: Kokubo, Y, et al.
Publicado: (2005)

Targeting the epidermal growth factor receptor
por: El-Rayes, B F, et al.
Publicado: (2004)

Laminin-5 offsets the efficacy of gefitinib (‘Iressa’) in hepatocellular carcinoma cells
por: Giannelli, G, et al.
Publicado: (2004)

Tyrosine kinase inhibitors and human epidermal growth factor receptor-2 positive breast cancer
por: Abunada, Aya, et al.
Publicado: (2023)

Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors
por: Fischel, J-L, et al.
Publicado: (2005)

Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells
por: Camirand, Anne, et al.
Publicado: (2005)

The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours
por: Knight, Louise A, et al.
Publicado: (2004)

Review of epidermal growth factor receptor-tyrosine kinase inhibitors administration to non-small-cell lung cancer patients undergoing hemodialysis
por: Lan, Chou-Chin, et al.
Publicado: (2022)

Epidermal growth factor signalling and bone metastasis
por: Lu, X, et al.
Publicado: (2010)

Recent advances and new insights in the management of early-stage epidermal growth factor receptor-mutated non-small-cell lung cancer
por: Sotelo, Miguel J, et al.
Publicado: (2021)

ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases
por: Cappuzzo, F, et al.
Publicado: (2003)

Human epidermal growth factor receptor 2 targeted therapy in endometrial cancer: Clinical and pathological perspectives
por: Saito, Ayumi, et al.
Publicado: (2021)

Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation
por: Noro, Rintaro, et al.
Publicado: (2006)

Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth
por: Traish, A M, et al.
Publicado: (2009)

Biomarkers of clinical benefit for anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancer
por: Pallis, A G, et al.
Publicado: (2011)

Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126
por: Bozec, A, et al.
Publicado: (2006)

Liquid biopsy to detect resistance mutations against anti-epidermal growth factor receptor therapy in metastatic colorectal cancer
por: Valenzuela, Guillermo, et al.
Publicado: (2022)

Gefitinib for Epidermal Growth Factor Receptor Activated Osteoarthritis Subpopulation Treatment
por: Sun, Heng, et al.
Publicado: (2018)

Symmetrical drug-related intertriginous and flexural exanthema secondary to epidermal growth factor receptor inhibitor gefitinib
por: Copps, Beatrice, et al.
Publicado: (2020)

Lessons from the ‘Iressa’ Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations
por: Stahel, R, et al.
Publicado: (2003)

Phase I/II study of gefitinib (Iressa(®)) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer
por: Han, Ji-Youn, et al.
Publicado: (2015)

Epidermal growth factor receptor mutation in combination with expression of MIG6 alters gefitinib sensitivity
por: Naruo, Yoshimi, et al.
Publicado: (2011)

Gefitinib in the treatment of nonsmall cell lung cancer with activating epidermal growth factor receptor mutation
por: Nurwidya, Fariz, et al.
Publicado: (2016)

The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models
por: Ribback, Silvia, et al.
Publicado: (2016)

Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR
por: Yang, Hua, et al.
Publicado: (2016)

Role of insulin-like growth factor 1 receptor signalling in cancer
por: Larsson, O, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_3kjm1eupg0e83l9t8imgah822f